Milestone pharmaceuticals inc. (MIST)
Income statement / Yearly
Dec'19Dec'18
Operating expenses
Research and development, net of tax credits (note 6)

41,985

16,849

General and administrative

7,004

3,052

Commercial

8,892

3,921

Loss from operations

-57,881

-23,822

Interest income, net of bank charges

2,596

711

Loss and comprehensive loss before income taxes

-55,285

-23,111

Income tax expense

-56

74

Net loss and comprehensive loss for the period

-55,229

-23,185

Weighted average number of shares outstanding, basic and diluted

15,784

319

Net loss per share, basic and diluted (note 5)

3.50

72.63